Calmactin

Treatment for Irritable Bowel Syndrome

Cilansetron; Solvay Pharmaceuticals Suspends Registration Activites in the U.S., While Discussions in Europe Continue

On average, IBS affects more than 11% of the EU population, with total annual direct costs estimates of some £45 million in the UK alone. The common symptoms of D-IBS are diarrhea, abdominal pain/discomfort, and fecal urgency. IBS has a significant, negative impact on the quality of life for the many men and women who suffer from this condition, causing lost days of work and interfering as well with home-based, social and leisure activities.

Source: Solvay Pharmaceuticals

Posted: November 2005

Related Articles

Calmactin (cilansetron) FDA Approval History

View comments

Hide
(web2)